Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery
Silk Road Medical, Inc. (Nasdaq: SILK) announced positive results from the TransCarotid Artery Revascularization (TCAR) Surveillance Project, published in the Annals of Surgery.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical, Inc. (Nasdaq: SILK) announced positive results from the TransCarotid Artery Revascularization (TCAR) Surveillance Project, published in the Annals of Surgery. The study demonstrated lower rates of in-hospital complications such as myocardial infarction (0.5% for TCAR vs. 0.9% for carotid endarterectomy) and cranial nerve injury (0.4% vs. 2.7%). Outcome rates for in-hospital stroke and death were similar between the two procedures (1.6%). These findings may enhance TCAR's role in treating carotid artery stenosis, as stated by CEO Erica Rogers, supporting its adoption as the standard of care.
Positive
- Lower in-hospital myocardial infarction rates (TCAR: 0.5%; CEA: 0.9%) indicating enhanced safety.
- Significantly lower cranial nerve injury rates with TCAR (0.4% vs. 2.7%).
- Hospital stay duration shorter for TCAR patients (26.4% vs. 30.1% for CEA).
- Positive peer-reviewed publication in the Annals of Surgery strengthens the credibility of the TCAR procedure.
Negative
- None.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was -3.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that positive results from the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project comparing TCAR and carotid endarterectomy (CEA) have been published in Annals of Surgery1.
“These results continue to show low in-hospital stroke, death, and combined stroke/death rates as well as statistically lower rates of in-hospital cranial nerve injury and in-hospital myocardial infarction compared to CEA,” said Dr. Mahmoud Malas, Chief of Vascular and Endovascular surgery at UC San Diego Health. “These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.”
The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 6,384 patients in each group analyzed using propensity score matching. TCAR was associated with significantly lower rates of in-hospital myocardial infarction (TCAR,
“The publication of these data in the Annals of Surgery further validates the effectiveness of TCAR as a treatment option for patients with carotid artery disease, while highlighting the consistency of these data,” said Erica Rogers, Chief Executive Officer. “We are confident that the updated results from the TCAR Surveillance Project, taken together with the recent publication of ROADSTER 2 data in Stroke, will continue to drive adoption of TCAR towards the standard of care.”
The TCAR Surveillance Project, a key initiative of the Society for Vascular Surgery’s Vascular Quality Initiative (VQI), is an open-ended registry intended to compare real-world patient outcomes between TCAR and other alternatives.
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR (TransCarotid Artery Revascularization) is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investors:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com
Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com
1 Mahmoud B. Malas MD, MHS; Hanaa Dakour-Aridi MD; Vikram S. Kashyap MD, et al. TransCarotid Revascularization with Dynamic Flow reversal versus Carotid Endarterectomy in the Vascular Quality Initiative Surveillance Project. Annals of Surgery. September 15, 2020; 322(23):2313-2322. DOI: 10.1097/SLA.0000000000004496
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.